INSR and type 2 diabetes mellitus: TXNIP is a mediator of insulin resistance in liver, skeletal muscle and adipose tissue, and impaired pancreatic beta-cell insulin secretion [23,24,25] and TNFα decreases insulin receptor signaling in adipose tissue and skeletal muscle, particularly prior to development of T2DM [26,27,28].